Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma

Journal of Surgical Oncology

Volumn 93, Issue 5, 2006, Pages 379-386

  Eltabbakh, Gamal H ^a   Mount, Sharon L ^b   Beatty, Barbara ^b   Simmons Arnold, Linda ^b   Cooper, Kumarasen ^b  

^a Lake Champlain Gynecologic Oncology   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell cycle; Chemoresistance; p53

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE REGULATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR MODEL; OVARY CARCINOMA; PAPILLARY SEROUS OVARY CARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOEMBOLISM; ADENOCARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; APOPTOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTADENOCARCINOMA, PAPILLARY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VERMONT;

EID: 33646200542     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20494     Document Type: Article

References (42)

1. Sheets EE, Yeh J: The role of apoptosis in gynecological malignancies. Ann Med 1997;9:121-126.
2. Bu SZm, Yin DL, Ren XH: Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;9:1944-1950.
3. Yamasaki F, Tokunga O, Sugimori H: Apoptic index in ovarian carcinoma: Correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997;66:439-448.
4. Diebold J, Barretton G, Felchner M, et al.: Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-349.
5. Hockenbery D, Nunez G, Milliam C, et al.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
6. Marone M, Scambia G, Mozzetti S, et al.: Bcl-2, bax, bcl-xL, and bcl-xs expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998;4:517-524.
7. Witty JP, Jensen RA, Johnson AL: Expression and localization of bcl-2-related proteins in human ovarian cancers. Anticancer Res 1998;18:1223-1230.
8. Marx D, Binder C, Meden H, et al.: Differential expression of apoptosis-associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997;17:2233-2240.
9. Berek JS, Martinez-Maza O: Molecular and biological factors in the pathogenesis of ovarian cancer. In: Sharp F, Mason P, Blackett T, editors. Ovarian cancer 3. London: Chapman & Hall Medical; 1995. pp 77-87.
10. Goff BA, Paley PJ, Greer BE, et al.: Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol 2001;81:18-24.
11. Kennedy AW, Biscottis CV, Hart WR, et al.: Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349.
12. Serov SF, Scully RE, Sobin LH, editors. Histologic typing of ovarian tumors (International histological classification of tumors. No. 9). Geneva: World Health Organization; 1973. pp 17-54.
13. Yoonessi M, Weldon D, Satchidand SK, et al.: Clear cell ovarian adenocarcinoma. J Surg Oncol 1984;27:289-297.
14. Jenison EL, Montag AG, Griffiths T, et al.: Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
15. Crozier MA, Copeland LJ, Silva EG, et al.: Clear cell carcinoma of the ovary. A study of 59 cases. Gynecol Oncol 1989;35:199-203.
16. Goff BA, Sainz de la Cuesta R, Muntz HG, et al.: Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417.
17. Kennedy AW, Markman M, Biscotti CV, et al.: Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol 1999;74:108-114.
18. Behbakht K, Randall TC, Benjamin I, et al.: Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-258.
19. Sugyama T, Kamura T, Kigawa N, et al.: Clinical characteristics of clear cell carcinoma of the ovary. A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589.
20. Silverberg SG: Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol 2000;19:7-15.
21. WHO; WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
22. Cancer Committee of the International Federation of Gynecology and Obstetrics: Staging announcement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383.
23. Kastan MB: Molecular biology of cancer: The cell cycle. In: DeVita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology, 5th edition. Philadelphia: Lippinocott-Raven Publishers; 1997. pp 121-134.
24. Young RC: Principles of chemotherapy in gynecologic cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practices of gyneoclogic oncology, 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1997. pp 381-397.
25. Chambers SK: Gynecologic Cancer. In: DeVita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology, 5th edition. Philadelphia: Lippinocott-Raven Publishers; 1997. pp 121-134.
26. Buller AL, Clapper ML, Tew KD: Glutathione S-transferases in nitrogen mustard-resistant and sensitive cell lines. Mol Pharmacol 1987;31:575-578.
27. O'Dwyer PJ, Johnson SW, Hamilton TG: Cisplatin and its analogues. In: DeVita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology, 5th edition. Philadelphia: Lippinocott-Raven Publishers; 1997. pp 121-134.
28. Eltabbakh GH, Belinson JL, Kennedy AW: p53 overexpression is not an independent prognostic factor in patients with primary ovarian epithelial cancer. Cancer 1997;80:892-898.
29. Levesque MA, Katsros D, Yu H, et al.: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-1338.
30. Klemi PI, Pylkkanen L, Kiiholma P, et al.: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1996;76:1201-1208.
31. Allan LA, Campbell MK, Milner BJ, et al.: The significance of p53 mutation and overexpression in ovarian cancer prognosis. Int J Gynecol Cancer 1996;6:483-490.
32. Mukhopadadyay T, Maxwell SA, Roth JA: Wild-type versus mutant p53. In: Mukhopadadyay T, Maxwell SA, Roth JA, editors. Molecular biology intelligence unit P53 suppressor gene. New York: Springer Verlag; 1995. pp 19-27.
33. Casey G, Lopez ME, Ramos JC, et al.: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known alterations in human malignancies. Oncogene 1996;13:1971-1981.
34. Sjorgen S, Inganas M, Norberg T, et al.: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-182.
35. Righetti SC, Torre GD, Pilotti S, et al.: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinboma. Cancer Res 1996;56:689-693.
36. Shimizu Y, Kamoi S, Amada S, et al.: Toward the development of a universal grading system for orian epithelial carcinoma. Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
37. Recio FO, Piver MS, Hempling RE, et al.: Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:157-163.
38. Ho ES, Lai C-R, Hsieh Y-T, et al.: p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001;80:189-193.
39. Shimizu M, Nikaido T, Toki T, et al.: Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-677.
40. Ferrandina G, Fagotti A, Salerno MG, et al.: p53 over-expression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999;81:733-740.
41. Buttitta F, Marchetti A, Gadducci A, et al.: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study. Br J Cancer 1997;75:230-235.
42. Sato S, Kigawa J, Minagawa Y, et al.: Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999;86:1307-1313.